Gynecologic Cancers

Linked to expansion of health insurance coverage.

Women who develop ovarian cancer are more likely to have better outcomes if they took oral contraceptives prior to their diagnosis, according to a new study by researchers at Mayo Clinic.

Women at an elevated risk of breast cancer may be able to avoid preventive procedures with regular aerobic exercise, according to a new study published in Breast Cancer Research and Treatment.

Genetic counseling before BRCA genetic testing improves patient knowledge, understanding, and satisfaction. However, a new analysis has found that most women undergoing BRCA genetic testing did not receive counseling prior to testing, despite national guidelines and recommendations.

In the past 12 months, women have been more likely to have seen their primary physician, dentist, eye doctor, and hairdresser than their OBGYN, according to results of a new survey.

Sharsheret is a national not-for-profit organization supporting young Jewish women and their families facing breast cancer and ovarian cancer.

Rates of endometrial cancer continue to increase among all racial and ethnic groups, but they're rising faster among non-Hispanic black women who also have poorer outcomes when compared with their white, non-Hispanic counterparts.

Study finds long-term survival is not unusual.

Less than 50% of patients with ovarian cancer who could benefit from intraperitoneal chemotherapy actually receive it, despite research suggesting that this technique could improve survival for these patients.

Oral contraceptives may provide long-term protection against endometrial cancer.

Findings of a new study show that failure to follow professional practice guidelines for weight-based chemotherapy dosing can lead to poorer survival in women with ovarian cancer.

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the importance of informed decision-making.

Sue Friedman, discusses the ABOUT Network, which is the first-ever patient-powered research registry created and governed by and for people affected by hereditary breast and ovarian cancers.

Deborah Watkins Bruner, PhD, RN, FAAN, from the Nell Hodgson Woodruff School of Nursing at Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.

Women who are at high risk of ovarian cancer are more likely to undergo preventive ovary removal if they are proactively offered genetic counseling, a new study has found.

Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib (Lynparza) in the treatment of women with ovarian cancer, Ursula A. Matulonis, MD, explained during a plenary session at the 2015 Society of Gynecologic Oncology's Annual Meeting on Women's Cancer.

Treatment with bevacizumab (Avastin) plus chemotherapy resulted in a non-statistically significant improvement in overall survival (OS) of nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

A new study has found that a psychosocial telephone counseling intervention helps improve mood and quality of life in cervical cancer survivors.

Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of bevacizumab and olaparib, and intraperitoneal chemotherapy (IP), have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines in its 20th annual edition.

A new analysis has shown that taking hormone replacement therapy to alleviate symptoms associated with menopause significantly increases the risk of developing the two most common types of ovarian cancer, even if the therapy is only taken for a few years.

Camille Grammer, Real Housewife of Beverly Hills and one-year survivor of endometrial cancer, will lend her voice and celebrity to raising awareness about gynecologic cancers by serving as Chair of the 2015 National Race to End Women's Cancer to be held Sunday, Nov. 8 in Washington, D.C.

Jessica Goldberg, MSN, adult gerontology nurse practitioner, fellow in palliative medicine, Memorial Sloan Kettering Cancer Center, discusses the results of a study in which a cancer self-management intervention was created for patients with breast cancer.

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing. In the past 18 months, the floodgates for testing options have opened, as companies seek to enter the diagnostic market in the wake of the US Supreme Court's June 2013 ruling that "naturally occurring" human genes are a "product of nature" and cannot be patented, breaking Myriad Genetics' monopoly on BRCA1/2 gene testing.

The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer. The approval was based on results from a single-arm phase II study of patients with deleterious or suspected deleterious germline BRCA-mutated advanced cancers

Jessica Goldberg, MSN, adult gerontology nurse practitioner, fellow in palliative medicine, Memorial Sloan Kettering Cancer Center, discusses a study on creating a successful cancer self-management intervention for patients with breast cancer.